Dracen Pharmaceuticals

United States
Rosedale, Indiana, United States, 21202

Company profile

Dracen Pharmaceuticals company profile

Dracen Pharmaceuticals is a developer of novel glutamine antagonists created to deliver improved outcomes for cancer patients and potentially extend the benefits of immuno-oncology therapies. The company develops novel glutamine antagonists with direct anti-tumor apoptotoc properties as well as endogenous anti-tumor immune modulatory mechanisms which increases the number of responders to anti-cancer therapy and extend survival for anti-tumor responses in areas currently evading immuno-oncology approaches.

Business identity

Contact email
[email protected]
Phone number
(917) 398-3710
Operating status
Active
Company type
For Profit
Employee range
1-10 employees
Revenue range
$0-$1M
Founded
2016-01-01, Year

Headquarters

Postal code
21202
Country code
US
Continent
North America

Capital profile

Funding and company signals

Funding rounds
3
Total equity funding
$48.6M
Last funding
Debt Financing / $2.3M / 2023-08-10
Last equity funding
Series Unknown / $8.6M
Investors
3
Lead investors
1
Founders
1
Articles
9

Founders and investors

Founders

Tom Estok

Lead investors

Deerfield

Investors

Deerfieldi&i PragueOUP (Osage University Partners)